Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study

SIMPLE SUMMARY: Idelalisib, the first-in-class phosphatidylinositol 3-kinase inhibitor, approved by the Italian Medicines Agency for the treatment of relapsed/refractory follicular lymphoma patients, showed high antitumor activity with an acceptable safety profile in a phase II registration trial. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadei, Beatrice, Argnani, Lisa, Broccoli, Alessandro, Patti, Caterina, Stefani, Piero Maria, Cuneo, Antonio, Margiotta Casaluci, Gloria, Visco, Carlo, Gini, Guido, Pane, Fabrizio, D’Alò, Francesco, Luzi, Debora, Cantonetti, Maria, Pozzi, Samantha, Musuraca, Gerardo, Rosignoli, Chiara, Arcari, Annalisa, Kovalchuk, Sofya, Tani, Monica, Tisi, Maria Chiara, Petrini, Mario, Stefoni, Vittorio, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833724/
https://www.ncbi.nlm.nih.gov/pubmed/35158922
http://dx.doi.org/10.3390/cancers14030654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833724/
https://www.ncbi.nlm.nih.gov/pubmed/35158922
http://dx.doi.org/10.3390/cancers14030654

Ejemplares similares